Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Stryker Biotech |
---|---|
Information provided by: | Stryker Biotech |
ClinicalTrials.gov Identifier: | NCT00456157 |
The purpose of this research study is to investigate the safety and tolerability of OP-1 when it is injected into the knee joint of patients who have osteoarthritis on the knee.
Condition | Intervention | Phase |
---|---|---|
Osteoarthritis of the Knee |
Drug: Intra-articular Injection of OP-1 to affected knee |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety Study |
Official Title: | A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-Articular Osteogenic Protein-1 OP-1 in Subjects With Osteoarthritis of the Knee |
Estimated Enrollment: | 33 |
Study Start Date: | March 2007 |
Study Completion Date: | November 2008 |
Subjects with OA will be recruited and informed consent obtained. During a screening period lasting 1 to 28 days, subjects will undergo medical and arthritis history, physical examination, collection of concomitant medications, KOOS (which contains the WOMAC questionnaire), SF-36 and global 100 mm VAS assessments, have samples obtained for urinalysis, hematology, chemistry, immunology and serum and plasma for future biomarker testing, ECG, bilateral knee x-rays and MRI of the index knee at selected sites. Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be randomized into the first cohort of 8 subjects to receive either 1.0 mL lactose (placebo) (2 subjects) or 1.0 mL OP-1 (6 subjects) intraarticularly using ultrasound or fluoroscopy guidance in an outpatient setting on day 1. Each cohort will consist of 8 treated patients, with treatment allocation in a 3:1 active-to-lactose (placebo) ratio. After an observation period of at least one hour, subjects will be released and contacted via telephone on Day 2 to query for AEs and concomitant medications. Additional follow-up visits will be done on days 7, 14, 28, 56, 84 and 168 (weeks 1, 2, 4, 8, 12 and 24) and safety and efficacy parameters evaluated according to the Schedule of Events. When a minimum of 4 weeks have elapsed since the last patient of the current cohort has been treated, all safety data will be collected and reviewed by the Principal Investigators and the Sponsor. The safety review will be conducted to ensure the demonstrated safety profile of OP-1 is acceptable for the treated patients. Only after the current dose level has been judged to be safe will dose escalation to the next dosing cohort occur.
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Boston University Medical Center | |
Boston, Massachusetts, United States, 02118-2526 | |
Tufts-New England Medical Center | |
Boston, Massachusetts, United States, 02111 | |
United States, North Carolina | |
University of orth Carolina School of Medicine | |
Chapel Hill, North Carolina, United States, 27599-7280 |
Responsible Party: | Stryker Biotech ( Gina Smith ) |
Study ID Numbers: | 06-OA-001 |
Study First Received: | April 3, 2007 |
Last Updated: | June 1, 2009 |
ClinicalTrials.gov Identifier: | NCT00456157 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Osteoarthritis Osteophytes Knee Intra-articular OP-1 |
Osteoarthritis, Knee Musculoskeletal Diseases Osteoarthritis |
Joint Diseases Arthritis Rheumatic Diseases |
Osteoarthritis, Knee Musculoskeletal Diseases Osteoarthritis |
Joint Diseases Arthritis Rheumatic Diseases |